Positron emission tomography imaging in nonsmall-cell lung cancer
- PMID: 17896784
- DOI: 10.1002/cncr.23051
Positron emission tomography imaging in nonsmall-cell lung cancer
Abstract
Positron emission tomography (PET) using 18F-2-deoxy-D-glucose, a D-glucose analog labeled with fluorine-18, complements conventional radiologic assessment in the evaluation of patients with nonsmall-cell lung cancer (NSCLC). PET is being routinely used to improve the detection of nodal and extrathoracic metastases. PET is also currently being evaluated in the assessment of prognosis and therapeutic response and by potentially allowing an earlier assessment of response may prove invaluable in the oncologic management of patients. The article discusses the diagnosis, staging, and assessment of treatment response and prognosis with an emphasis on the appropriate clinical use of PET in management.
(c) 2007 American Cancer Society.
Similar articles
-
Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.J Thorac Imaging. 2011 May;26(2):132-46. doi: 10.1097/RTI.0b013e3182128704. J Thorac Imaging. 2011. PMID: 21508735 Review.
-
Value of FDG PET in the management of NSCLC.Lung Cancer. 2004 Aug;45 Suppl 2:S75-8. doi: 10.1016/j.lungcan.2004.07.989. Lung Cancer. 2004. PMID: 15552785 Review.
-
Prognosis and reevaluation of lung cancer by positron emission tomography imaging.Proc Am Thorac Soc. 2009 Apr 15;6(2):171-9. doi: 10.1513/pats.200806-059LC. Proc Am Thorac Soc. 2009. PMID: 19349485 Review.
-
Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?Chest. 2004 Sep;126(3):755-60. doi: 10.1378/chest.126.3.755. Chest. 2004. PMID: 15364753
-
Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).J Exp Clin Cancer Res. 2008 Oct 17;27(1):52. doi: 10.1186/1756-9966-27-52. J Exp Clin Cancer Res. 2008. PMID: 18928537 Free PMC article. Review.
Cited by
-
Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature.Diagnostics (Basel). 2020 Aug 5;10(8):561. doi: 10.3390/diagnostics10080561. Diagnostics (Basel). 2020. PMID: 32764429 Free PMC article. Review.
-
[18F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT.Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1685-1694. doi: 10.1007/s00259-024-07064-3. Epub 2025 Jan 6. Eur J Nucl Med Mol Imaging. 2025. PMID: 39760863
-
Current and future lymphatic imaging modalities for tumor staging.Biomed Res Int. 2014;2014:714674. doi: 10.1155/2014/714674. Epub 2014 Mar 16. Biomed Res Int. 2014. PMID: 24757671 Free PMC article. Review.
-
A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer.J Clin Med. 2024 Apr 30;13(9):2633. doi: 10.3390/jcm13092633. J Clin Med. 2024. PMID: 38731161 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
